HEPATITIS B REACTIVATION RISK IN PATIENTS WITH RHEUMATOLOGIC DISEASES UNDER BIOLOGIC TREATMENT

Basit Öğe Kaydı
dc.contributor.authorGokcen, Pinar
dc.contributor.authorAltinkaya, Engin
dc.date.accessioned2024-10-26T18:07:19Z
dc.date.available2024-10-26T18:07:19Z
dc.date.issued2021
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractIntroduction: Hepatitis B virus reactivation (HBVr) is a clinical entity that can occur due to the use of immunosuppressive medications and causes serious complications that can threaten survival. In this study, we aimed to investigate the effects of the biological agents used in rheumatology on HBVr in a large patient population. Materials and methods: Patients with rheumatologic diseases who were on biological treatment were analyzed according to hepatitis B virus (HBV) serology. Patients with resolved HBV and inactive chronic HBV were included in the study. Prophylaxis status, HBVr and hepatic flare were recorded. Results: 749 patients were screened by medical records. 106 (14.2%) patients were in the resolved HBV group and 15 (2%) patients were inactive HBV carrier. Prophylaxis was not administered to 74 (69.8 %) patients in the resolved HBV group and 4 (26.7%) patients in the inactive chronic HBV group. None of the patients demonstrated HBVr. Conclusion: We suggest that long-term prophylactic oral antiviral treatment can be avoided by the close follow-up of patients who were on tumour necrosis factor a (TNF a) or cytokine inhibitors due to low HBVr risk. On the other hand, patients receiving rituximab must be more carefully evaluated to prevent patients from not receiving antiviral prophylaxis.
dc.identifier.doi10.19193/0393-6384_2021_3_244
dc.identifier.endpage1533
dc.identifier.issn0393-6384
dc.identifier.issn2283-9720
dc.identifier.issue3
dc.identifier.scopus2-s2.0-85107916556
dc.identifier.scopusqualityN/A
dc.identifier.startpage1529
dc.identifier.urihttps://doi.org/10.19193/0393-6384_2021_3_244
dc.identifier.urihttps://hdl.handle.net/20.500.12418/29455
dc.identifier.volume37
dc.identifier.wosWOS:000661101800037
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherCarbone Editore
dc.relation.ispartofActa Medica Mediterranea
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectcytokine inhibitors
dc.subjecthepatitis B reactivation
dc.subjectrheumatology
dc.subjectresolved HBV
dc.subjectrituximab
dc.subjectTNF a inhibitors
dc.titleHEPATITIS B REACTIVATION RISK IN PATIENTS WITH RHEUMATOLOGIC DISEASES UNDER BIOLOGIC TREATMENT
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu